Abstract: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.

Abstract: A liposome composition having a high drug concentration of a hydrophobic drug and capable of retaining the drug in entrapped form is described. The liposomes are comprised of high phase transition lipid and a lipopolymer, which together permit retention of a high concentration of a drug/cyclodextrin complex that achieves a high drug load that is retained even in the presence of a transmembrane osmotic gradient caused by the cyclodextrin.

Abstract: Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

Abstract: The present invention relates to coated capsules with increased capsule shell pliability and resilience and methods of making the coated capsules. The present invention relates to methods of making coated capsules, the methods comprising applying a coating solution comprising sodium carboxymethylcellulose or sodium alginate to the exterior of a capsule to form a coating and drying the coating to produce a coated capsule.

Abstract: The invention relates to the use of absorbable block copolymers with polyether and polyester units for preparing surgical implants which are suitable for the human or animal body, and the block copolymers in question. The block copolymers used according to the invention and those which are new according to the invention are characterised by high mechanical strength and rapid absorption kinetics.

Abstract: The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of C. difficile, C. perfringens, or S. aureus.

Abstract: The present invention relates to dispersible tablets of cephalexin and a process for their preparation.

Abstract: In a solid pharmaceutical preparation containing water-soluble salts of levothyroxine and/or liothyronine as active ingredients, the water activity of said pharmaceutical preparation is adjusted to values of below 0.4 and, preferably, 0.1 to 0.3, measured at room temperature.

Abstract: The invention provides a novel “separation marking” on a tablet as a means for assisting in the identification of a region on the tablet that is desired to be able to be broken from time to time. Said breaking allows production of smaller dosage forms known herein as tablettes. In a preferred embodiment, the separation mark will be a printed mark that is made on the tablet surface.

Abstract: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose.

Abstract: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose.

Abstract: Stable pharmaceutical compositions of desloratadine or pharmaceutically acceptable salts in combination with one or more therapeutically active compounds.

Abstract: The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid dispersion, wherein it contains a salt substance that comprises an alkali and a weak or strong acid and has an endothermic standard enthalpy of solution or heat of solution. Since rapid disintegration of the pharmaceutical composition of the present invention and rapid dissolution of the medicament contained in the preparation can be made in the digestive tracts pH-independently, good bioavailability can be attained.

Abstract: The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state in an atomized matrix, in addition to an alkaline agent and an adsorbing agent, a method for the production thereof and a method for masking the taste of pharmaceutical products.

Abstract: An osmotically controlled delivery system includes a solid core having a shallow indentation on a surface of the core, and a semipermeable membrane enclosing the solid core. The solid core is made by a drug composition being caopable of generating an osmotically effective pressure, and the semipermeable membrane is relatively thinner at the shallow indentation. An in-situ exit passageway is formed in the indentation position when external aqueous fluids are imbibed through the semipermeable membrane into the dosage form by an osmotic pressure gradient. A process for forming an in-situ exit passageway of an osmotic delivery dosage form, a controlled onset dosage form, and a method for controlling the lag time of in-situ passageway formation are also disclosed.

Abstract: An oral, highly bioavailable unit dosage form of O-desmethylvenlafaxine succinate (DVS) having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours is described. In one embodiment, the superbioavailable DVS composition has a delayed release of about two hours and a total release of greater than about 95% within about 12 to about 14 hours. Use of the formulation in treating depression and reducing the gastrointestinal side-effects of O-desmethylvenlafaxine (ODV) is also described.

Abstract: A method for treatment of esophagitis is disclosed in which a therapeutic composition is introduced into the esophagus to contact a mucosal surface within the esophagus. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.

Abstract: A method for treatment of proctitis is disclosed in which a therapeutic composition is introduced into the rectum to contact a mucosal surface within the rectum. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.

Abstract: A hemostatic agent comprises oxidized cellulose in the form of a compressible, shapeable mass that can remain substantially in the compressed or shaped form for placement on a bleed site or into a wound gap. The oxidized cellulose may be a pellet of unwoven oxidized cellulose fibrous strands, or it may be strands of unwoven cellulose fibers woven or otherwise arranged into a gauze or mesh. In a method of causing hemostasis, oxidized cellulose is provided in pellet form and applied to a wound gap. The pellet may be compressed before being applied to the wound, which thereby allows the pellet to expand to conform to the shape of the wound gap. The pellet may be allowed to remain in the wound gap during the healing of the wound, thus causing the pellet to be absorbed by the biological processes of the body.

Abstract: Nanoparticles containing retinoic acid have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes them suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application. The present invention provides a method for adjusting the particle size of such nanoparticles and nanoparticles produced by such a method. Specifically, the method involves dispersing retinoic acid dissolved in a lower alcohol in an aqueous alkali solution; adding a nonionic surfactant to the dispersion to form a mixed micelle; adding to the micelle a halide or acetate of divalent metal along with a carbonate or phosphate of alkali metal so that the molar ratio of the former to the latter is 1:0 to 1:1.

Abstract: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose.

Abstract: Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate are prepared using a substantially dry granulation process including an agitative balling process. In a preferred embodiment, spherically shaped acephate granules are produces without the intentional addition of water and/or solvents.

Abstract: Synergistic therapeutic compositions for reducing triglycerides, lowering LDL and increasing HDL are formed by combining either pantethine or CoA, or a combination of pantethine and CoA with fish oils. Either pantethine or CoA, or a combination of pantethine and CoA, added to cardiovascular drugs or compositions for lowering cholesterol increases the therapeutic effects and decreasing the side effects of those drugs or compositions. Either pantethine or CoA, or a combination of pantethine and CoA, added to drugs or compositions used in the treatment of Type I or Type II diabetes also increases the therapeutic effects and decreasing the side effects of those drugs or compositions.

Abstract: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted into an osteochondral or bone defect. A method for repair and restoration of the injured, damaged, diseased or aged cartilage or bone into its full functionality by implanting the acellular matrix implant between two layers of biologically acceptable sealants and/or the bone-inducing composition into the osteochondral bone or skeletal bone defect. A method for fabrication of the acellular matrix implant of the invention. A method for preparation of bone-inducing composition.

Abstract: The invention is a patch for partial closure of the pericardial sac after open heart surgery. The patch comprises extracellular matrix material and is loosely tacked at the opening of the pericardium. The invention provides the opportunity for subsequent open heart surgeries without the risks involved in negotiating around the adhesions that can develop when the sac is left completely unclosed.

Abstract: The invention is to a composition for reconstruction, replacement or repair of a defect in or dsmage to intracardiac tissue comprising a patch, emulsion, injectable solution or other composition comprising extracellular matrix. As extracellular matrix can assimilate with the intracardiac tissue to help generate healthy functioning tissue, using extracellular matrix to address a defect in intracardiac tissue can obviate the need for second or subsequent open heart surgeries, or if the composition can be delivered in a minimally invasive medical procedure, can obviate the need for open heart surgery altogether. Conduction of the intracardiac tissue may also be restored using extracellular matrix material to reconstruct, replace or repair the damaged intracardiac tissue.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.

Abstract: The present invention discloses a novel drug delivery system for proton pump inhibitors comprising benzimidazole compounds or their salts, preferably Rabeprazole or its salts and pharmaceutically acceptable excipients in powder form which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.

Abstract: The present invention relates to synergistic compositions for protection against oxidative damage, consisting essentially of antacids in conjunction with antioxidants. The invention further relates to method for preventing oxidative damage using the compositions of the invention.

Abstract: The present invention relates to the use of extracts from Pelargonium species or plant parts thereof, particularly from P. sidoides and P. reniforme for the prophylaxis or treatment of disease-related behavioural changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these extracts.

Abstract: Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions may comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea extract, guarana, yerba matè powder, dandelion root extract, juniper berry powder, parsley powder garcinia cambogia extract, cayenne pepper powder extract, n-acetyl-l-tyrosine, quercetin dehydrate, gynostemma pentaphyullum extract, vinpocetine and optionally thiamin, pyridoxine, picamilone, xanthinol nicotinate, garcinia cambogia extract and niacin.

Abstract: The present invention relates to a composition comprising Notoginseng radix extract for preventing and treating arthritis as an effective ingredient. Notoginseng radix extract of the present invention inhibits release of tumor necrosis factor-alpha (TNF-?) and is the death of activated T-cells only, so that it can be effectively used for the production of a medicine for preventing and treating arthritis and health food as well.

Abstract: The present invention relates to a method for preparing an extract from ginkgo biloba having a reduced content of nonpolar plant ingredients and nonpolar impurities due to environmental influences compared to the initial extract, the method being characterized by the following method steps: (a) preparing an aqueous-ketonic or aqueous-alcoholic solution of an initial ginkgo biloba extract and applying the solution to an adsorber resin, (b) eluting the adsorber resin with an aqueous C3-C6 ketone or an aqueous C1-C3 alcohol and (c) optionally concentrating and drying the extract solution thus obtained to the dry extract. The invention further relates to an extract (liquid extract or spissum extract as well as dry extract) from ginkgo biloba having a reduced content of nonpolar plant ingredients and nonpolar impurities due to environmental influences compared to the initial extract, which is obtainable by the method of the present invention.

Abstract: A process of skin treatment to soften the skin and minimize wrinkles utilizes in the first step the spray application of a mist to the skin. This first step is followed by the application of a mixture of beneficial vegetable oils that with essential oils. The first step of the treatment facilitates the absorption of the beneficial oils in the second step. As the composition and process also provides for the firming and toning of breast tissue, it promotes a daily regimen of efficient examination critical in the early self-discovery of abnormal tissue, which may be malignant. The preferred compositions are optimized to facilitate the breast self-examination process, providing an appropriate level of lubricity for an extended time without an oily residue.

Abstract: A compound comprising blood-thinning and or anti-coagulant ingredients mixed with ellagic acid and/or ellagitannin, said compound-taken orally.

Abstract: The invention relates to methods for treating osteoarthritis by administering a composition consisting essentially of proanthocyanidins to a patient suffering from such a disorder.

Abstract: A molding apparatus includes a moving mold for shaping molten plastic into product made within the moving mold. The moving mold is surrounded by an air block housing to define a cooling chamber exteriorly around the moving mold. At least one heat exchanger is located within the cooling chamber. The heat exchanger provides cooling air which is contained by the housing within the cooling chamber to act on and provide cooling of the moving mold.

Abstract: A blank carrying/filling apparatus including: a bed member having a body section, at least one tunnel with a predetermined diameter extending through the body section from a back face to a front face thereof; at least one blank carrying section for carrying a blank; a thrust body having at least one thrust member slidable disposed in the tunnel and movable between a blank carrying position and a blank releasing position, whereby when the thrust member is positioned in the blank releasing position, the thrust member via physical action force disconnects the blank carrying section and the blank carried by the blank carrying section and releases the blank; and a driving member for forcing the thrust member to move between the blank carrying position and the blank releasing position.

Abstract: An apparatus for forming microstructures in the surface of polymeric web materials for use as optical memory substrates. The microstructures may be formed by laminating a hot stamper to a web of material with a selective time/temperature profile. The stamper may be heated to melt flow the surface of the web and stabilize before separation. The stamper may be carried by a support that is independent of the press. The web of polymeric material may be provided with a flow enhancer to improve image formation. Also described herein are methods and apparatus for making optical memory modules, such as disks, which include novel stampers, coating applicators, and finishing systems.

Abstract: A chewing gum delivery system has nicotine, gum base and a buffer system with an improved release rate for the nicotine. The resulting delivery system advantageously provides a convenient, reliable, practical, and relatively painless system for delivering an active. The delivery system is capable of delivering initial and second doses of a craving reduction active or other actives (e.g., nicotine), the combination of which rapidly reduces cravings, or provides some other pharmacological effect, and provides the pharmacological effect or protection from such cravings over a prolonged period of time beyond the initial dose. Notably, the delivery system is capable of rapidly achieving a pharmacologically effective concentration of the active (e.g., nicotine) in the bloodstream (e.g.

Abstract: Novel cooling compositions having a natural status are object of the present invention. These compositions comprise a combination of menthol, together with a nature identical ingredient and at least one natural extract. They can be added to flavoring compositions to impart cooling sensations devoid of mentholic flavoring notes.

Abstract: The invention is a multi-phase, sheeted chewing gum product, a method and an apparatus for making such a product. The product includes a first mass of a chewing gum formed in a generally flat sheet and a second mass of a confectionery product having a different color than the first mass. The second mass is smaller than the first mass and is embedded in the first mass so as to be visible with the first mass from the top surface of the chewing gum. The method includes the steps of forming the first mass into a slab with a generally flat surface. The second mass is formed into at least one piece which is brought into contact with the flat surface. The slab and the piece are pressed to produce a generally flat sheet which is cut into segments of a desired width, length and shape.

Abstract: There are provided genetically modified yeasts with the capability to form a biofilm at the liquid/air interphase, as well as processes for obtaining fungi and yeasts with the capability to form a biofilm with those features, and uses thereof.

Abstract: The invention relates to frozen, developed dough compositions, and related methods. Dough compositions of the present invention include a yeast ingredient, an enzyme that facilitates the production of hydrogen peroxide in the dough composition (preferably glucose oxidase), and optional acid and base chemical leavening agent. Dough compositions according to the present invention can be proofed via yeast leavening at a wide variety conditions, such as at ambient temperature or at retarder temperature.

Abstract: A method comprising selection of unbroken whole grain rice that are first washed, or whole grain corn that is first reduced in size, and then making an aqueous slurry that is subsequently wet milled to release all the protein, fat, fiber, and starch components normally held in the structure of the grain. The resulting slurry can be reacted with heat to gelatinize the starch and the subsequent product dried. Also, the heated slurry containing the liberated components can be treated to enzymatic hydrolysis via the process of liquefaction and optionally saccharification, producing whole grain rice milk products having diverse carbohydrate compositions.

Abstract: An apparatus for and method of processing cheese milk and producing cheese therefrom. The apparatus includes a pair of vats each having an inlet and an outlet. The outlet of the first vat is connected to the inlet of the second vat by a conduit. The second vat is mounted lower than the first vat to enable a gravity feed therebetween. A de-waterer removes whey is provided between the two vats, where the de-waterer is controlled by a pair of valves. One valve is provided in an exhaust from the de-waterer and the other valve is provide between the de-waterer and the second vat. Both vats have stirers mounted therein. The stirer in the first vat is mounted to cut any coagulum that may form therein. The stirer in the second vat is mounted to agitate and provided substantially no cutting of any coagulum that may form therein.